Trial Profile
A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Otelixizumab (Primary) ; Methylprednisolone
- Indications Graves ophthalmopathy
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 15 Oct 2014 New trial record